Seglutide (semaglutide) is a human glucagon-like peptide-1 (GLP-1) receptor agonist, engineered with 94% homology to native human GLP-1. Its molecular structure is optimized for a prolonged half-life of approximately one week, allowing for convenient once-weekly subcutaneous administration. Its mechanism of action includes stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner, delaying gastric emptying, and acting on brain centers to reduce hunger and enhance satiety.

The therapeutic applications for Seglutide have expanded significantly. Initially established as a cornerstone therapy for adults with type 2 diabetes to improve glycemic control and reduce the risk of major adverse cardiovascular events (MACE), its indications now encompass a broader spectrum of metabolic diseases. These include:

Chronic Weight Management: For adults and adolescents (12+) with obesity or overweight with comorbidities.
Cardiovascular Risk Reduction: For adults with established cardiovascular disease and either obesity or overweight.
Kidney Protection: To reduce the risk of kidney function decline and end-stage kidney disease in adults with T2DM and CKD.
Liver Health (MASH): A groundbreaking indication for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (F2-F3).

Extensive clinical data from the SUSTAIN trial program underscores Seglutide's efficacy. Across multiple head-to-head trials, semaglutide demonstrated superior reductions in both HbA1c and body weight compared to placebo, other GLP-1 RAs (like dulaglutide and exenatide ER), DPP-4 inhibitors, and SGLT-2 inhibitors. The landmark SUSTAIN 6 cardiovascular outcomes trial revealed a significant 26% reduction in the risk of MACE (CV death, non-fatal MI, or non-fatal stroke) versus placebo.

While effective, treatment requires careful consideration of its safety profile. Seglutide is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Key warnings include the risk of acute pancreatitis, gallbladder disease, and potential gastrointestinal adverse reactions like nausea and vomiting, which are most common during dose initiation. Notably, rapid improvement in glucose control has been associated with a temporary worsening of pre-existing diabetic retinopathy, requiring patient monitoring.

This profile highlights Seglutide's robust clinical data and its evolving role as a multi-faceted agent for managing complex, interrelated metabolic conditions. For complete dosing, administration, and safety information, healthcare professionals should consult the full product monograph. For more information click here.

Seglutide (Semaglutide): A Comprehensive Clinical Profile for Diabetes, Weight Management, and Liver Health